Focus on Janus Kinase Inhibitors in Rheumatoid Arthritis

In this downloadable slideset, Gregg J. Silverman, MD, and William F. C. Rigby, MD, discuss the indications, mechanisms of action, and recent pivotal trial data regarding Janus kinase inhibitors in the management of rheumatoid arthritis.
Format: Microsoft PowerPoint (.ppt)
File Size: 1.14 MB
Released: August 1, 2016


Supported by an educational grant from
Lilly USA, LLC

Related Content

CCO faculty Dr. Jonathan Kay’s viewpoint on data from 2019 ACR/ARP on novel approaches for treatment of RA

Jonathan Kay, MD Physicians: maximum of 0.25 AMA PRA Category 1 Credits Released: January 9, 2020 Expiration: January 8, 2021

CCO faculty Dr. Stanley Cohen’s viewpoint on data from 2019 ACR/ARP on investigational and approved JAK inhibitors for RA

Stanley B. Cohen, MD Physicians: maximum of 0.25 AMA PRA Category 1 Credits Released: December 5, 2019 Expiration: December 4, 2020

7-year baricitinib safety data in RA patients consistent with earlier reports and acceptable considering efficacy from 2019 ACR, as reported by CCO; safety evaluations ongoing

Released: November 25, 2019

Latest data on IRAK4 inhibitor PF-06650833 in moderately to severely active RA presented at ACR/ARHP 2019 as reported by Clinical Care Options (CCO)

Released: November 18, 2019

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.


Welcome to the CCO site.

You are accessing CCO's educational content today as a Guest user.

If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.


More info

CCO’s educational programs are available completely free of charge on the,, and Web sites. Certain features and functions are restricted for Guest users. By consenting to become a full member, you are eligible to receive CME/CE credit or participation certificates from certified activities, to register for CCO’s free live meetings and webinars, and to receive CCO’s email newsletters alerting you to new content. You can unsubscribe from our emails at any time. CCO strictly protects the privacy of our members, according to our privacy policy.

A confirmation email will be sent to . Not You?